Biogen talks up approval plans for controversial Alzheimer’s drug as it nears FDA decision

Biogen Inc.'s first-quarter earnings beat expectations, but investors may be paying more attention to the latest information the company is sharing about its plans for aducanumab, the experimental Alzheimer’s disease drug that has sent the stock on a wild ride.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.